Introduction
Many of the morbidities and limitations of postnatal bone marrow transplantation (BMT) could be avoided by utilizing in utero hematopoietic stem cell transplantation (IUHSCT). Disease candidates that look promising for human application of IUHSCT include many congenital enzyme, hematologic, and immune deficiencies [1, 2] . Complications of postnatal BMT include toxicities of required immunosuppressive therapies and graft-versushost disease (GVHD). Furthermore, less than 25% of recipients will have an HLA-matched donor.
Limited engraftment has been a major obstacle in previous attempts at human IUHSCT. To date, the only clear successes have been with X-linked severe combined immunodeficiency likely secondary to a competitive advantage for donor cells [3, 4] . We have developed a model of IUHSCT in fetal canines [5] which, similar to humans, develop immunocompetence prior to birth [6] , in order to investigate the roles of donor cell dosing and gestational age in engraftment and GVHD. This study is an
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The development of the canine fetal immune system shares similarities with humans that are relevant to a preclinical model of IUHSCT [6] . Unlike rodents, dogs appear to be immunologically mature at birth [7] . The canine fetus first exhibits bacteriophage recognition at 40 gestational days (term day 63) despite the fact that at this age there is no peripheralization of lymphoid cells [8] . Peripheralization of lymphocytes begins to occur on days 45-50 [7] . Thymectomy of the 48-gestational-day dog produces deficient humoral antibody and cellular hypersensitivity responses [9] . The earliest detectable antibody production occurs on ∼ day 56 [8] .
Previous work by others has proposed a gestational age 'window of opportunity' which permits successful engraftment and avoidance of GVHD following IUHSCT [10] . The 'window of opportunity' for IUHSCT should precede the establishment of host immunologic competence. On the other hand, IUHSCT performed too early might be less successful during the rapid cellular expansion of fetal host hematopoietic cells. The aim of this study was to investigate the optimal time in gestation for IUHSCT in a canine model.
Materials and Methods

Animals
Eight bred animal pairs (maternal-paternal pairs) were procured (from American Association for Accreditation in Laboratory Animal Care-approved facilities) for IUHSCT on post-fertilization days 31-50 (term day 63). This work was performed under a Johns Hopkins University School of Medicine-approved animal care protocol. The animal facility at the Johns Hopkins University is certified by the American Association for Accreditation in Laboratory Animal Care and adheres to the guidelines for proper animal care set by the American Veterinary Medical Association.
Donor HSC Preparation
Paternal donor canine BM was harvested the day prior to the planned IUHSCT. Under general anesthesia, the marrow was aspirated from the long bones and hips of the male donor. Mononuclear cells were isolated from the donor marrow using a Ficoll gradient and labeled with mouse anti-canine CD34 IgG1 (clone 1H6; FHCRC, Seattle, Wash., USA) followed by rat anti-mouse microbeads. CD34+ selection was then performed using a magnetic column (Miltenyi Biotec, Auburn, Calif., USA) and the positive fraction was used for transplantation. Alternatively, the ficolled BM fraction was used for transplantation in which the percent CD34+ cells were calculated and ficolled cell number adjusted to achieve the desired CD34+ cells/kg dosage. Aliquots of each stage of purification were saved and analyzed for purity by flow cytometry using mouse anti-canine CD34 (clone 2E9; Pharmingen, San Diego, Calif., USA) directly conjugated to phycoerythrin for FACS (fluorescence-activated cell sorting) analysis. For each experiment, we sought to employ a high CD34+ donor cell dose per kilogram which tended to decrease as gestational age and fetal weight increased ( table 1 ).
Donor T-Cell Preparation
Paternal canine donor peripheral blood was harvested the day prior to planned BM harvest. We sought to achieve T-cell doses of 1 × 10 8 to 1 × 10 9 cells/kg. Using a Ficoll gradient, mononuclear cells were isolated from the donor marrow and labeled using mouse anti-canine CD3 IgG1 followed by rat anti-mouse microbeads. CD3+ selection was then performed using a magnetic column (Miltenyi Biotec) and the positive fraction was collected. Aliquots were obtained and analyzed for purity by flow cytometry using anti-canine CD3 and CD5 directly conjugated to fluorescein isothiocyanate and phycoerythrin, respectively, for FACS analysis. On the day of the transplant, CD34+ and T cells were washed, recounted, assessed for viability, and admixed at the desired doses. T-cell doses ranged from 1.1 × 10 8 to 1.1 × 10 9 T cells/kg.
IUHSCT Procedure
Transdermal sonography to verify gestational age and viability was performed upon arrival of the pregnant bitch [11] . Thirtyone to 50 days after fertilization, laparotomy was performed under general anesthesia to expose the uterus and to allow intraoperative sonography using a strict aseptic technique. The fetal crown-rump lengths in this study ranged from 1.9 to 10.6 cm. Using established norms, the fetal weight was estimated (formula: L = 21W 0.389 ) [12] . Under ultrasound guidance, intraperitoneal fetal injections were then performed using HSCs and T cells (study animals) or ethiodol dye (controls) [5] . Between 1 and 4 pups per litter served as recipients depending upon the amount of donor cells collected at the time of the paternal BM harvest. Fetal cardiac motion was confirmed and the abdomen was closed. Serial transdermal sonography was performed to assess fetal viability and growth after transplantation. A radiograph was obtained at birth of each pup to identify the presence (control pup) or absence (recipient pup) of intraperitoneal radiopaque ethiodol. Postnatal Studies for Engraftment and GVHD After sacrifice within the first few days of life, necropsies were performed on both recipient and control pups. Tissue samples were submitted for histology and DNA engraftment analysis, including hematopoietic tissues (blood, BM, liver, spleen, and thymus), brain, kidney, heart and tissues where GVHD would be most likely to occur (skin, large intestine, and tongue).
TaqMan SRY Quantitative PCR. In order to quantify the amount of engraftment in female transplant recipients, a quantitative PCR assay specific to the SRY gene (on the Y-chromosome) was used. Duplicate reactions were prepared using 2× real-time PCR master mix (Applied Biosystems, Foster City, Calif., USA), forward primer = CCCCATGAACGCATTCTTG, reverse primer = CTGATCTCTGAGTTTTGCATTTGG, and probe = TCTC-GCGATCAAAGG, labeled on the 5 ′ end with FAM and on the 3 ′ end with NFQ. Quantification was accomplished by comparison to a standard curve. A real-time quantitative assay was developed for a control gene (factor V) to monitor the quantity and quality of the DNA from the various tissues. The assay has a linear range of detection from 100 to 0.01%.
Microsatellite PCR Reactions. In order to quantify the amount of engraftment in recipients of either sex, microsatellite PCR and capillary electrophoresis were performed using the StockMarks fluorescent PCR reagents (Applied Biosystems). Ten microsatellite loci were amplified in duplicate from the paternal, maternal and pup DNA samples. PCR products were analyzed on an ABI 3100 genetic analyzer (Applied Biosystems). Paternal, maternal and pup alleles were identified and compared to select 'informative' microsatellite loci at which unique donor alleles could potentially be identified if engraftment had occurred. At each of the informative loci, the capillary electrophoresis data from the pups were assessed for evidence of the unique donor alleles. Quantification was performed by comparison of the peak heights of the unique donor alleles to the peak heights of the pup alleles. The formal limit of detection for this assay is 5%; however, the true limit of detection for an individual reaction is both locus and PCR dependent. Although engraftment can often be detected below 5%, quantification at this level is not as accurate.
Statistical Analysis
The primary statistical objective of this study was to determine the optimal timing for IUHSCT by comparing engraftment across gestational ages and in different target tissues. The litters were divided into three categorical groups: early (days 31-37), mid (days 38-46), and late (days 47-50), and Kruskal-Wallis one-way analysis of variance was used to compare the median level of engraftment in each group across various target tissues. To compare the range of engraftment within groups, the Moses test of extreme reaction was utilized. Values of p < 0.05 were considered statistically significant.
Results
We performed 8 canine IUHSCT experiments at the gestational ages indicated in table 1 . HSC doses ranged from 0.09 to 3.4 × 10 9 CD34+ cells/kg. T-cell (CD3+/ CD5+) doses ranged from 1.1 × 10 8 to 1.1 × 10 9 cells/kg. The CD34+ purity determined by FACS analysis ranged from 50 to 78% and was used to calculate the CD34+ dose in cells per kilogram. The overall term pup survival in these experiments was 85% (44/52 animals). The survival rate in recipients was similar with 20/21 (95%) surviving to birth. This rate of survival is consistent with previous work using this model [5] . Control pups were identified in all cases (by intraperitoneal presence of ethiodol). There were a total of 20 recipient neonates from whom tissues were evaluated for engraftment and histologic evidence of GVHD ( table 1 ) . There was no clinical or histologic evidence of GVHD noted in any of the IUHSCT cases.
We observed microchimerism in nonhematopoietic organs in all but the day-31 transplant recipient. Higher engraftment levels were seen in hematopoietic tissues (range 0-10%). When engraftment in hematopoietic tissues was compared against gestational age at the time of IUHSCT, we observed a trend towards higher engraftment levels in the mid range of our gestational ages, with a peak in the middle range of gestation. Perhaps more importantly, this same trend was observed when we analyzed engraftment in whole blood and BM alone. Engraftment peaked at 42 days of gestation at the time of IUHSCT with engraftment in both blood and BM of 7.5%. Little to no engraftment was present at the extremes of our gestational age range, despite higher donor cell doses at earlier fetal ages. Data from all recipients are presented in table 2 ; female recipients were analyzed with SRY quantitative PCR and microsatellite PCR with good agreement between the two methods; male recipients could only be analyzed with microsatellite PCR.
When the litters were stratified into groups, the median percent engraftment differed between early, mid, and late subjects only for spleen and blood (p = 0.047 and p = 0.026, respectively; table 3 ). For the spleen, the only difference that is statistically significant when categories were prepared is between early and mid (p = 0.020), and this difference is no longer significant after adjusting for multiple comparisons (p = 0.059; table 4 ). There is no significant difference between early and late, or between mid and late. For blood, the percent engraftment is significantly higher in the mid category than in the early category (p = 0.007 and p = 0.021, respectively, after adjusting for multiple comparisons; table 4 ). There is no significant difference between early and late, or between mid and late. Using the Moses test of extreme reaction, the only significant finding was that for blood: the mid group had a wider range than the early group (p < 0.001).
Discussion
IUHSCT is a promising therapy for the treatment of a number of human disorders. Although early human attempts have been limited by minimal engraftment, results in animal studies have been encouraging [13] . In order to progress towards human trials, preclinical animal models are essential.
The theoretical benefits of IUHSCT are numerous. [14] .
The canine model has several apparent benefits over other large animal models of IUHSCT. (1) The availability of canine CD34 antibodies allows for purification of HSC from donor BM [15] . (2) The availability of CD3 and CD5 canine antibodies allows purification of T cells from the peripheral blood [16] . (3) Canines have a relatively short gestational length compared to other animal models. (4) Canine litter size allows multiple fetal infusions to be performed within the same gestation. (5) The canine experiences few obstetrical complications and their uterus is tolerant to surgical manipulation. (6) Future treatment trials and modeling for human applications are possible because canines have many analogous medical conditions [17, 18] . Using this model, our results suggest that fetal age at the time of injection of paternally derived HSCs may play a key role in achieving engraftment. From our data, a gestational age window at ∼ 42 days may permit maximal engraftment opportunity, without GVHD, in the fetal canine. One major limitation of this study, however, was the lack of long-term observation in recipient offspring. A longer period of follow-up would have allowed the determination of long-term engraftment, immune reconstitution, and a better analysis for evidence of GVHD to include determination of whether the observed imbalance of levels of donor cells in peripheral blood versus BM might have represented early GVHD. Theoretically, engraftment levels seen in the blood in the mid-gestational age window approached those which, if sustained, could be therapeutic in hemoglobinopathies [19, 20] . With only a brief period of follow-up, it is difficult to ascertain the engraftment/reconstitution of HSCs. The SRY-positive cell lineages could represent progenitor or residual donor cells rather than engrafted HSCs. Another limitation of this study is the technical difficulties at the extremes of gestation. At early gestation, this procedure is technically challenging, and at later gestation achieving high enough cell dosages is difficult. This resulted in few recipients at the extremes of gestational age and could be an explanation for the variation in engraftment observed.
IUHSCT can create low level chimerism at birth that allowed donor-specific tolerance HCST 'boosting' BM transplant in a minimally conditioned animal, reversing the lethal phenotype of canine leukocyte adhesion deficiency [21] . This deviation from our protocol is important because the CD34 cell dose we utilized is unlikely to be achievable in human treatment.
Our work supports the concept that at early gestational ages, rapid proliferation of fetal host hematopoietic cells may prohibit engraftment [22] . However, at later gestational ages, maturation of the fetal immunologic response may lead to graft rejection. In the canine, immune maturation is nearly complete between days 45 and 55, and during this same time, the BM becomes heavily cellular with abundance of HSCs [6] . Although extensive data are lacking, this corresponds to a human fetal age of 16-20 weeks, an estimated gestational age at which time fetal intervention is possible [6] . A window in gestation in which host cellular proliferation is slowing, yet spaces for donor cells to occupy are still available and/or evolving, may prescribe the optimal time to perform IUHSCT [22] .
Future studies will focus further on cell dosing within the gestational age window of 38-46 days to determine parameters for maximal engraftment in this mammalian model of IUHSCT. Within these gestational age studies, it will be important to maintain a fixed cell dose of both CD34 and T-cell numbers to assure accurate delineation of the optimal gestational age. Other areas of investigation will include long-term engraftment studies and attempts to determine cellular doses that achieve GVHD in the canine model. Ultimately, we hope to test the therapeutic potential of engraftment achieved through IUH-SCT in canine models of human disorders. Studies in animal models such as the canine will provide a framework for advancing IUHSCT towards human application.
